How would you approach a patient with well controlled metastatic lung cancer who develops a new primary P16 positive oropharyngeal squamous cell carcinoma?  

Is it reasonable to dose de-escalate since survival will likely depend on the metastatic lung cancer?



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution